title: [Clinical evaluation of norfloxacin in children].
abstract: Oral new quinolone, norfloxacin (NFLX, AM-715), was evaluated for its safety, efficacy and pharmacokinetics in children. 1. NFLX was effective in 88.0% of 25 cases infected with Haemophilus influenzae, Pseudomonas aeruginosa, Escherichia coli, Campylobacter jejuni, Staphylococcus aureus including methicillin-resistant strains, and other bacteria. 2. After single oral administration of 50 mg and 100 mg NFLX tablet at fasting, mean peak values of serum concentration were 0.35, 0.48 microgram/ml and T1/2 values were 2.2, 2.7 hours, respectively. 3. No adverse reactions suggestive for arthropathy were encountered with NFLX therapy with daily doses of 4.6-35.7 mg/kg (maximum 600 mg per day) and duration of 3 to 19 days. From these preliminary data, NFLX seems to have a place in the treatment of pediatric infectious diseases.
authors.affiliation: Department of Pediatrics, School of Medicine, Teikyo University.
authors.forename: H
authors.initials: H
authors.lastname: Meguro
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: K
authors.initials: K
authors.lastname: Ushijima
authors.forename: C
authors.initials: C
authors.lastname: Nonaka
authors.forename: T
authors.initials: T
authors.lastname: Shinozaki
authors.forename: R
authors.initials: R
authors.lastname: Fujii
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000367:Age Factors; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D009643:Norfloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013607:Tablets
chemical_list: D013607:Tablets; D009643:Norfloxacin